logo
logo

Spotlight Therapeutics Closes $30M Series A Led by GV to Advance Pipeline of Non-viral CRISPR Gene Editing Biologics

Nov 30, 2020•almost 5 years ago

Amount Raised

$30 Million

Round Type

series a

San Francisco

Description

Spotlight Therapeutics, Inc., a biotechnology company developing non-viral gene editing therapeutics for direct in vivo editing of target genes, closed its Series A financing bringing the total raised to $30 million. The financing was led by GV, formerly Google Ventures, with participation from additional undisclosed investors.

Company Information

Company

Spotlight Therapeutics

Location

San Francisco, California, United States

About

Established in mid-2018, Spotlight Therapeutics is a privately held biotechnology company advancing a pipeline of cell-targeted in vivo CRISPR gene editing therapies. Spotlight's proprietary technology platform TAGE (Targeted Active Gene Editors) is a new class of biologics, CRISPR effectors engineered for direct delivery in vivo, to achieve cell-selective therapeutic genome editing. Spotlight's pipeline is advancing its modular programmable CRISPR effectors towards clinical studies in immuno-oncology, ophthalmic diseases and hemoglobinopathies. The company is headquartered in Hayward, California. For more information, please visit www.spotlighttx.com.

Related People

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech